{"id":57443,"date":"2023-05-19T22:03:16","date_gmt":"2023-05-19T20:03:16","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/exicure-inc-received-nasdaq-delinquency-notice-on-late-filing-of-its-form-10-q\/"},"modified":"2023-05-19T22:03:16","modified_gmt":"2023-05-19T20:03:16","slug":"exicure-inc-received-nasdaq-delinquency-notice-on-late-filing-of-its-form-10-q","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/exicure-inc-received-nasdaq-delinquency-notice-on-late-filing-of-its-form-10-q\/","title":{"rendered":"Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q"},"content":{"rendered":"
\n

CHICAGO–(BUSINESS WIRE)–Exicure, Inc. (\u201cExicure\u201d or the \u201cCompany\u201d) (Nasdaq: XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC (\u201cNasdaq\u201d) on May 17, 2023 notifying the Company that, as a result of the Company\u2019s failure to timely file its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023 (the \u201cForm 10-Q\u201d), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the \u201cRule\u201d), which requires listed companies to timely file all periodic financial reports with the U.S. Securities and Exchange Commission (the \u201cSEC\u201d).<\/p>\n

<\/a><\/p>\n

\nUnder Nasdaq\u2019s listing rules, Exicure has 60 calendar days to submit a plan to regain compliance. If the plan is accepted by Nasdaq, the Company can be granted up to 180 calendar days from the Form 10-Q due date, or until November 13, 2023, to regain compliance.<\/p>\n

\nThe Company is working diligently to complete its Form 10-Q and intends to file the Form 10-Q as soon as practicable to regain compliance with the Rule.<\/p>\n

\nAbout Exicure<\/b><\/p>\n

\nExicure, Inc. has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. Following its recent restructuring and suspension of clinical and development activities, the Company is exploring strategic alternatives to maximize stockholder value, both with respect to its historical biotechnology assets and more broadly. For further information, see www.exicuretx.com<\/a>.<\/p>\n

\nForward-Looking Statements<\/b><\/p>\n

\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical fact may be deemed forward looking including, but not limited to, statements regarding: the Company\u2019s current business plans and objectives, including the pursuit of strategic alternatives to maximize stockholder value. Words such as \u201cplans,\u201d \u201cexpects,\u201d \u201cwill,\u201d \u201canticipates,\u201d \u201ccontinue,\u201d \u201cadvance,\u201d \u201cbelieves,\u201d \u201ctarget,\u201d \u201cmay,\u201d \u201cintend,\u201d \u201ccould,\u201d and other words and terms of similar meaning and expression are intended to identify forward-looking statements, although not all forward-looking statements contain such terms. Forward-looking statements are based on management\u2019s current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company\u2019s actual results to differ from those contained in the forward-looking statements, see the section titled \u201cRisk Factors\u201d in the Company\u2019s Annual Report on Form 10-K for the year ended December 31, 2022 filed with the Securities and Exchange Commission on March 27, 2023, as updated by the Company\u2019s subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information or to publicly announce the results of any revisions to any of such statements to reflect future events or developments, except as required by law.<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia:<\/b>
Karen Sharma
\n
MacDougall
\n
781-235-3060
\n
ksharma@macdougall.bio<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

CHICAGO–(BUSINESS WIRE)–Exicure, Inc. (\u201cExicure\u201d or the \u201cCompany\u201d) (Nasdaq: XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC (\u201cNasdaq\u201d) on May 17, 2023 notifying the Company that, as a result of the Company\u2019s failure to timely file its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023 … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-57443","6":"format-standard","7":"category-industry"},"yoast_head":"\nExicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/exicure-inc-received-nasdaq-delinquency-notice-on-late-filing-of-its-form-10-q\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"CHICAGO–(BUSINESS WIRE)–Exicure, Inc. (\u201cExicure\u201d or the \u201cCompany\u201d) (Nasdaq: XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC (\u201cNasdaq\u201d) on May 17, 2023 notifying the Company that, as a result of the Company\u2019s failure to timely file its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023 ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/exicure-inc-received-nasdaq-delinquency-notice-on-late-filing-of-its-form-10-q\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-19T20:03:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230519005369\/en\/651600\/21\/Exicure_Logo_FINAL_Full_Color-072515.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exicure-inc-received-nasdaq-delinquency-notice-on-late-filing-of-its-form-10-q\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exicure-inc-received-nasdaq-delinquency-notice-on-late-filing-of-its-form-10-q\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q\",\"datePublished\":\"2023-05-19T20:03:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exicure-inc-received-nasdaq-delinquency-notice-on-late-filing-of-its-form-10-q\\\/\"},\"wordCount\":494,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exicure-inc-received-nasdaq-delinquency-notice-on-late-filing-of-its-form-10-q\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230519005369\\\/en\\\/651600\\\/21\\\/Exicure_Logo_FINAL_Full_Color-072515.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exicure-inc-received-nasdaq-delinquency-notice-on-late-filing-of-its-form-10-q\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exicure-inc-received-nasdaq-delinquency-notice-on-late-filing-of-its-form-10-q\\\/\",\"name\":\"Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exicure-inc-received-nasdaq-delinquency-notice-on-late-filing-of-its-form-10-q\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exicure-inc-received-nasdaq-delinquency-notice-on-late-filing-of-its-form-10-q\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230519005369\\\/en\\\/651600\\\/21\\\/Exicure_Logo_FINAL_Full_Color-072515.jpg\",\"datePublished\":\"2023-05-19T20:03:16+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exicure-inc-received-nasdaq-delinquency-notice-on-late-filing-of-its-form-10-q\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exicure-inc-received-nasdaq-delinquency-notice-on-late-filing-of-its-form-10-q\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exicure-inc-received-nasdaq-delinquency-notice-on-late-filing-of-its-form-10-q\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230519005369\\\/en\\\/651600\\\/21\\\/Exicure_Logo_FINAL_Full_Color-072515.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230519005369\\\/en\\\/651600\\\/21\\\/Exicure_Logo_FINAL_Full_Color-072515.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exicure-inc-received-nasdaq-delinquency-notice-on-late-filing-of-its-form-10-q\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/exicure-inc-received-nasdaq-delinquency-notice-on-late-filing-of-its-form-10-q\/","og_locale":"en_US","og_type":"article","og_title":"Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q - Pharma Trend","og_description":"CHICAGO–(BUSINESS WIRE)–Exicure, Inc. (\u201cExicure\u201d or the \u201cCompany\u201d) (Nasdaq: XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC (\u201cNasdaq\u201d) on May 17, 2023 notifying the Company that, as a result of the Company\u2019s failure to timely file its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023 ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/exicure-inc-received-nasdaq-delinquency-notice-on-late-filing-of-its-form-10-q\/","og_site_name":"Pharma Trend","article_published_time":"2023-05-19T20:03:16+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230519005369\/en\/651600\/21\/Exicure_Logo_FINAL_Full_Color-072515.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/exicure-inc-received-nasdaq-delinquency-notice-on-late-filing-of-its-form-10-q\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/exicure-inc-received-nasdaq-delinquency-notice-on-late-filing-of-its-form-10-q\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q","datePublished":"2023-05-19T20:03:16+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/exicure-inc-received-nasdaq-delinquency-notice-on-late-filing-of-its-form-10-q\/"},"wordCount":494,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/exicure-inc-received-nasdaq-delinquency-notice-on-late-filing-of-its-form-10-q\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230519005369\/en\/651600\/21\/Exicure_Logo_FINAL_Full_Color-072515.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/exicure-inc-received-nasdaq-delinquency-notice-on-late-filing-of-its-form-10-q\/","url":"https:\/\/pharma-trend.com\/en\/exicure-inc-received-nasdaq-delinquency-notice-on-late-filing-of-its-form-10-q\/","name":"Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/exicure-inc-received-nasdaq-delinquency-notice-on-late-filing-of-its-form-10-q\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/exicure-inc-received-nasdaq-delinquency-notice-on-late-filing-of-its-form-10-q\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230519005369\/en\/651600\/21\/Exicure_Logo_FINAL_Full_Color-072515.jpg","datePublished":"2023-05-19T20:03:16+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/exicure-inc-received-nasdaq-delinquency-notice-on-late-filing-of-its-form-10-q\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/exicure-inc-received-nasdaq-delinquency-notice-on-late-filing-of-its-form-10-q\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/exicure-inc-received-nasdaq-delinquency-notice-on-late-filing-of-its-form-10-q\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230519005369\/en\/651600\/21\/Exicure_Logo_FINAL_Full_Color-072515.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230519005369\/en\/651600\/21\/Exicure_Logo_FINAL_Full_Color-072515.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/exicure-inc-received-nasdaq-delinquency-notice-on-late-filing-of-its-form-10-q\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/57443","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=57443"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/57443\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=57443"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=57443"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=57443"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}